Skye Bioscience 10-Q Details Redx Reverse Merger, $103.9M Financing, and 1-for-8 Reverse Split

summarizeSummary

Skye Bioscience's 10-Q details the Redx reverse merger terms, including $103.9M in financing, a 1-for-8 reverse split, and a going concern warning if the deal fails.

check_boxKey Events · M&A and Partnerships · SKYE

• Redx Reverse Merger Terms Quantified

  Skye will acquire Redx Pharma via a scheme of arrangement. Existing Skye shareholders will own approximately 5.38% of the combined company, Redx holders 46.17%, and financing investors 48.45%.

• Concurrent Financing of $67.9M

  Skye entered a Securities Purchase Agreement for $67.9 million (up to $72.9 million) with accredited investors, closing immediately after the merger. Redx separately raised $36.0 million in a Series A financing.

• Equity Line of Credit and Warrant

  A binding term sheet with Redmile Group provides for a $22.0 million equity line of credit over three years and a warrant to purchase up to $5.0 million of shares.

• 1-for-8 Reverse Stock Split

  Board approved a 1-for-8 reverse split on August 12, 2026, expected effective August 24, 2026, to regain Nasdaq's $1.00 minimum bid price requirement.

auto_awesomeAnalysis · SKYE · Life Sciences

The Q2 10-Q from Skye Bioscience puts hard numbers on the previously announced Redx Pharma reverse merger: a $67.9M concurrent financing (up to $72.9M), a $36M Series A, and a $22M equity line of credit. Existing Skye shareholders will own only 5.38% of the combined company. The filing also discloses a 1-for-8 reverse stock split effective August 24, 2026, to regain Nasdaq compliance, and a $3.25M increase in legal contingency reserves for the Cunning lawsuit. The company has a working capital deficit and substantial doubt about its ability to continue as a going concern if the transaction fails.